Credit Suisse Initiates Coverage On Viridian Therapeutics with Outperform Rating, Announces Price Target of $51
Credit Suisse analyst Tiago Fauth initiates coverage on Viridian Therapeutics (NASDAQ:VRDN) with a Outperform rating and announces Price Target of $51.